Skip to content

Effects of rare sugar D-allulose on brain, physiological, and psychological states

Effects of rare sugar D-allulose on brain, physiological, and psychological states

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
JPRN
Registry ID
JPRN-jRCT1041250108
Enrollment
20
Registered
2025-10-01
Start date
2025-10-01
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Increase in satiety (decrease in hunger), enhancement in positive affect Healthy Volunteers

Interventions

Oral administration of either 140mL aqueous Allulose (10g) and GABA (150mg) solution, 140mL queous Allulose (10g) solution, and 140mL Glucose (10g) solution, and 150mL Water
D000284, D005947, C003243, D005680
Administration Oral, Glucose, psicose (allulose), gamma-Aminobutyric Acid

Sponsors

Homma Shogo
Lead Sponsor
Ohira Hideki
Collaborator

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Healthy undergraduate and graduate students Aged 20-39 years Right handed Male Able to communicate fluently in Japanese Willing to participate, with sufficient understanding of the study contents, and able to provide written informed consent

Exclusion criteria

Exclusion criteria: Individuals who have a conflict of interest with the principal investigator or research collaborators (e.g., supervised graduate students, students currently enrolled in their classes) Current illness requiring medication Diagnosis of diabetes mellitus History of psychiatric or neurological disorders Presence of dermatological disorders History of neurosurgical procedures Current use of oral steroids Severe hepatic disease Severe infectious disease Perioperative status (before or after surgery) Severe trauma Dehydration Excessive alcohol consumption Malnutrition Starvation state General debilitation Pituitary insufficiency Adrenal insufficiency History of small intestine resection Presence of atrial fibrillation Body mass index (BMI) more than 25 Fasting blood glucose level more than 110 mg/dL

Design outcomes

Primary

MeasureTime frame
Electroencephalography (EEG), Electrocardiography (ECG), Electrogastrography (EGG), Respiration, Continuous blood pressure, Pupil diameter, Subjective ratings (satiety, hunger, emotional valence, arousal), Blood glucose level, Responses in the heartbeat counting task, Responses in the craving (preference rating) task

Secondary

MeasureTime frame
Questionnaire responses: Multidimensional Assessment of Interoceptive Awareness (MAIA), Body Perception Questionnaire - Body Awareness (BPQ-BA), Beck Depression Inventory (BDI), State-Trait Anxiety Inventory (STAI), Ten Item Personality Inventory (TIPI), Dutch Eating Behavior Questionnaire (DEBQ), Original questionnaire on dietary habits, Age, height, weight, Interview (physical and emotional changes during the experiment), Experience sampling method

Contacts

Public ContactShogo Homma

Graduate School of Informatics, Nagoya University

homma.shogo.g9@f.mail.nagoya-u.ac.jp+81-52-789-2263

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026